Bluechiip (BCT.AX) Stock Price
Bluechiip Price
Revenue has compounded at 30.4% per year over the past 12 years to 484,700.00 AUD. Bluechiip's net margin stands at -1,199.3%, up from -1,910.5% several years earlier.
Bluechiip stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Bluechiip over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bluechiip stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bluechiip's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Bluechiip Price |
|---|
Bluechiip Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Bluechiip Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESB |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | 1.00 | – | – | – | – | – | 6.00 | 8.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 33.33 |
| -4.00 | -3.00 | -3.00 | -2.00 | -1.00 | -1.00 | -1.00 | -2.00 | -3.00 | -4.00 | -3.00 | -3.00 | -5.00 | -5.00 | – | – |
| – | – | – | – | – | – | – | – | -300.00 | – | – | – | – | – | – | – |
| -3.00 | -2.00 | -3.00 | -2.00 | -1.00 | -1.00 | -2.00 | -2.00 | -3.00 | -4.00 | -3.00 | -3.00 | -5.00 | -5.00 | -1.00 | – |
| – | -33.33 | 50.00 | -33.33 | -50.00 | – | 100.00 | – | 50.00 | 33.33 | -25.00 | – | 66.67 | – | -80.00 | – |
| 0.07 | 0.08 | 0.10 | 0.12 | 0.15 | 0.18 | 0.28 | 0.39 | 0.50 | 0.57 | 0.63 | 0.63 | 0.75 | 1.18 | 1.18 | 1.18 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Bluechiip generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bluechiip retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bluechiip's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Bluechiip has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bluechiip's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Bluechiip stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Bluechiip Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Bluechiip business model & stock analysis
Bluechiip SWOT Analysis
Strengths
Bluechiip Ltd has several key strengths that contribute to its success in the market.
Bluechiip Ltd differentiates itself through its innovative technology, offering advanced tracking solutions utilizing MEMS-based sensors. This technology provides accuracy and reliability in various applications, such as healthcare and cold chain management.
The company has a strong portfolio of intellectual property, including patents and trademarks, which provides a competitive advantage and barriers to entry for potential competitors.
Bluechiip Ltd has established strategic partnerships with leading organizations in industries such as healthcare, pharmaceuticals, and logistics. These partnerships enhance the company's market reach and provide access to valuable distribution channels.
Weaknesses
Despite its strengths, Bluechiip Ltd also faces certain weaknesses that need to be addressed.
Bluechiip Ltd's market presence is relatively limited compared to some of its competitors. This may restrict its ability to capture a larger market share, especially in highly competitive markets.
The company's manufacturing capacity may be a potential weakness as it could limit its ability to scale production to meet increasing demand. This could lead to delays in delivering products to customers and potentially affect customer satisfaction.
Opportunities
Bluechiip Ltd can capitalize on emerging opportunities to further strengthen its position in the market.
The increasing need for efficient cold chain management in industries such as pharmaceuticals and food storage provides an opportunity for Bluechiip Ltd to expand its market presence and offer its innovative tracking solutions.
The ongoing advancements in the healthcare industry, including personalized medicine and biobanking, present opportunities for Bluechiip Ltd to provide its advanced tracking solutions for sample management and improved patient care.
Threats
Bluechiip Ltd faces certain threats that could impact its business operations and growth.
The market for tracking solutions is highly competitive, with the presence of established players and potential new entrants. Bluechiip Ltd must continuously differentiate itself and stay ahead of competitors to maintain and expand its market share.
Rapid technological advancements and evolving customer requirements pose a risk of Bluechiip Ltd's technology becoming obsolete if it fails to keep up with market trends and develop innovative solutions.
Bluechiip Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Bluechiip historical P/E ratio, EBIT multiple, and P/S ratio
Bluechiip annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Bluechiip shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Bluechiip shareholder structure
| % | Name |
|---|---|
5.63706% | |
2.20667% | |
1.48982% | |
0.72898% |
Bluechiip Executives and Management Board
4 members · 0 % women
Management
Mr. Andrew McLellan
Chief Executive Officer, Managing Director
Board of Directors
Mr. Iain Macgregor Kirkwood
Non-Executive Chairman of the Board, Company Secretary · since 2007
Mr. Andrew Cox
Non-Executive Independent Director
Mr. Michael Ohanessian
Non-Executive Independent Director
Frequently asked questions about Bluechiip
Bluechiip Ltd is an innovative technology company specializing in advanced tracking solutions. Founded in 2005, Bluechiip has revolutionized the way temperature-sensitive assets are monitored and tracked. The company's breakthrough technology combines both passive RFID and MEMS technologies to provide highly accurate and reliable identification of assets in extreme conditions. Bluechiip's patented product, the Bluechiip Smart, is leading the industry in healthcare, life sciences, and sample tracking. With a strong focus on innovation and continuous improvement, Bluechiip Ltd is committed to delivering cutting-edge tracking solutions to meet the evolving needs of its customers.
The business model of Bluechiip Ltd revolves around providing innovative tracking solutions for various industries. The company specializes in developing and commercializing advanced tracking technologies using its proprietary chip and software platform. Bluechiip's unique microchips enable real-time and robust tracking of valuable assets, such as biological samples, electronic components, and medical devices. By incorporating wireless communication and temperature sensing capabilities, Bluechiip's tracking solutions offer accurate monitoring and improved efficiency in inventory management. The company's technology finds applications in healthcare, pharmaceuticals, cryogenic storage, and logistics sectors, ensuring traceability and enhancing supply chain management. Bluechiip Ltd aims to deliver reliable and secure tracking solutions to facilitate seamless operations and safeguard valuable assets for its clients.
Bluechiip Ltd is primarily active in the healthcare and life sciences industries.
The main competitors of Bluechiip Ltd in the market include companies like Zymergen Inc., NanoString Technologies Inc., and Fluidigm Corporation.
Bluechiip Ltd has achieved several significant milestones. The company successfully developed its innovative wireless tracking solution, which combines a unique microchip with a passive RFID tag. Bluechiip's technology aims to revolutionize the storage and monitoring of critical biological samples, such as those used in healthcare and pharmaceutical industries. The company has also formed strategic partnerships with leading organizations in various sectors, including healthcare and biobanking, to showcase the potential of its solution. Bluechiip continues to enhance its product portfolio and expand its market reach, positioning itself as a key player in the field of advanced tracking and monitoring systems.
Bluechiip Ltd is primarily present in Australia.
Bluechiip Ltd represents values of innovation, reliability, and sustainability in its corporate philosophy. The company focuses on developing and commercializing advanced tracking solutions using its unique and patented technology. Bluechiip's solution provides a highly reliable, tamper-proof, and cost-effective method for tracking and monitoring critical samples, such as those used in healthcare, research, and logistics industries. With a commitment to continuous improvement and a customer-centric approach, Bluechiip aims to provide exceptional solutions that improve efficiency, reduce errors, and enhance overall operational effectiveness. As a result, Bluechiip Ltd sets itself apart as a leading provider of cutting-edge tracking technology solutions.
The Bluechiip share (BCT.AX) is listed on 2 stock exchanges, including: Frankfurt (1BL.F), ASX (BCT.AX).
Bluechiip Ltd is a leading provider of innovative solutions in the cryo-biology industry. The company specializes in developing sample management systems based on the unique Bluechiip technology to improve efficiency and accuracy in cryo-biology. The Bluechiip technology combines RFID and MEMS technology to identify samples even under extreme conditions of -196 degrees Celsius. It offers various products and solutions tailored to the needs of customers, including a sample management system with automatic sample tracking and real-time data monitoring. Bluechiip also partners with other companies in the cryo-biology industry to expand its product portfolio and develop new applications. The company invests in research and development to improve its product portfolio and develop new technologies. It focuses on markets such as biobanks, research institutions, cell therapy, clinical trials, and bioproduction and supply chain management. The Bluechiip technology provides enhanced data capture, increased security, and more efficient sample management solutions for the cryo-biology industry.
The expected revenue of Bluechiip is 8.29 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Bluechiip.
The P/E ratio cannot be calculated for Bluechiip at the moment.
The P/S cannot be calculated for Bluechiip currently.
The Eulerpool Quality Score for Bluechiip is 4/10.
The ISIN of Bluechiip is AU000000BCT7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Bluechiip is A1JFYH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Bluechiip is BCT.AX. The ticker symbol is used to trade Bluechiip shares on the stock exchange.
Bluechiip is assigned to the 'Information technology' sector.
The dividends of Bluechiip are distributed in AUD.
Bluechiip stock
Bluechiip Peer Group
Bluechiip Ticker
Bluechiip FIGI
All fundamentals and in-depth analysis of Bluechiip
Our stock analysis for Bluechiip stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bluechiip. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.